Circadian Rhythm Genes Are Biomarkers for Predicting Risk of Preterm Birth
By LabMedica International staff writers Posted on 17 Aug 2021 |

Structure of CLOCK circadian regulator (courtesy of: Wikimedia Commons)
The CLOCK and CRY2 genes have been identified as useful biomarkers for predicting the likelihood that a pregnant woman will experience a preterm birth.
Previous studies have observed an association between maternal circadian rhythm disruption and preterm birth. However, the underlying molecular mechanisms and the potential of circadian clock genes to serve as predictors of preterm birth remain unexplored.
Investigators at Michigan State University (East Lansing, USA) examined the association of 10 core circadian transcripts in maternal blood with spontaneous preterm births versus full term births using a nested case-control study design. For this study, maternal blood was sampled in trimesters two-three from women with spontaneous preterm births (n = 51) and full term births (n = 106), matched for five demographic variables.
Results revealed that in second trimester maternal blood, only CLOCK and CRY2 transcripts were significantly lower in spontaneous preterm births versus full term. In addition, the investigators identified 98 common pathways that were negatively or positively correlated with CLOCK and CRY2 expression.
CLOCK is a gene encoding a basic helix-loop-helix-PAS transcription factor that is believed to affect both the persistence and period of circadian rhythms. The CLOCK gene plays a major role as an activator of downstream elements in the pathway critical to the generation of circadian rhythms. In mammals, the proteins coded by the CRY1 and CRY2 genes act as light-independent inhibitors of CLOCK-BMAL1 components of the circadian clock.
“We were excited to discover lower mRNA levels in the CRY2 and CLOCK genes,” said senior author Dr. Hanne Hoffmann, assistant professor of animal science at Michigan State University. “Preterm births are common. If we know the mother is at risk for a preterm birth, her doctor can monitor her more closely. If we could measure women’s mRNA levels and tell them for their second or third pregnancies that they are not at risk for a preterm birth because their levels are higher (in a normal/healthy range), that would be such a comfort to the mothers who previously had a preterm birth. If I can help one baby make it to full term who was not supposed to, that would make my day.”
The preterm birth study was published in the June 18, 2021, online edition of the Journal Biology of Reproduction.
Related Links:
Michigan State University
Previous studies have observed an association between maternal circadian rhythm disruption and preterm birth. However, the underlying molecular mechanisms and the potential of circadian clock genes to serve as predictors of preterm birth remain unexplored.
Investigators at Michigan State University (East Lansing, USA) examined the association of 10 core circadian transcripts in maternal blood with spontaneous preterm births versus full term births using a nested case-control study design. For this study, maternal blood was sampled in trimesters two-three from women with spontaneous preterm births (n = 51) and full term births (n = 106), matched for five demographic variables.
Results revealed that in second trimester maternal blood, only CLOCK and CRY2 transcripts were significantly lower in spontaneous preterm births versus full term. In addition, the investigators identified 98 common pathways that were negatively or positively correlated with CLOCK and CRY2 expression.
CLOCK is a gene encoding a basic helix-loop-helix-PAS transcription factor that is believed to affect both the persistence and period of circadian rhythms. The CLOCK gene plays a major role as an activator of downstream elements in the pathway critical to the generation of circadian rhythms. In mammals, the proteins coded by the CRY1 and CRY2 genes act as light-independent inhibitors of CLOCK-BMAL1 components of the circadian clock.
“We were excited to discover lower mRNA levels in the CRY2 and CLOCK genes,” said senior author Dr. Hanne Hoffmann, assistant professor of animal science at Michigan State University. “Preterm births are common. If we know the mother is at risk for a preterm birth, her doctor can monitor her more closely. If we could measure women’s mRNA levels and tell them for their second or third pregnancies that they are not at risk for a preterm birth because their levels are higher (in a normal/healthy range), that would be such a comfort to the mothers who previously had a preterm birth. If I can help one baby make it to full term who was not supposed to, that would make my day.”
The preterm birth study was published in the June 18, 2021, online edition of the Journal Biology of Reproduction.
Related Links:
Michigan State University
Latest Microbiology News
- Viral Load Tests Can Help Predict Mpox Severity
- Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
- Credit Card-Sized Test Boosts TB Detection in HIV Hotspots
- Fecal Metabolite Profiling Predicts Mortality in Critically Ill Patients
- Portable Molecular POC System Rules Out UTIs in Just 35 Minutes
- POC Lateral Flow Test Detects Deadly Fungal Infection Faster Than Existing Techniques
- Rapid Diagnostic Test Slashes Sepsis Mortality by 39%
- Blood Culture Assay Enhances Diagnostic Stewardship Through Targeted Panel Selection
- Real-Time Genome Sequencing Detects Dangerous Superbug Causing Hospital Infections
- Diagnostic Test Accurately Detects Colorectal Cancer by Identifying Microbial Signature in Gut Bacteria
- Rapid Bedside Test Predicts Sepsis with Over 90% Accuracy
- New Blood Test Detects Up to Five Infectious Diseases at POC
- Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
- New Test Diagnoses Bacterial Meningitis Quickly and Accurately
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia
A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more
New Technique for Measuring Acidic Glycan in Blood Simplifies Schizophrenia Diagnosis
Polysialic acid is a unique acidic glycan predominantly found in brain regions associated with memory and emotion, but it is also present in the bloodstream. Research has shown that blood levels of polysialic... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read morePathology
view channel
AI Performs Virtual Tissue Staining at Super-Resolution
Conventional histopathology, essential for diagnosing various diseases, typically involves chemically staining tissue samples to reveal cellular structures under a microscope. This process, known as “histochemical... Read more
AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read moreTechnology
view channel
Inexpensive DNA Coated Electrode Paves Way for Disposable Diagnostics
Many people around the world still lack access to affordable, easy-to-use diagnostics for diseases like cancer, HIV, and influenza. Conventional sensors, while accurate, often rely on expensive equipment... Read more
New Miniature Device to Transform Testing of Blood Cancer Treatments
Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking treatment for blood cancers like leukemia, offering hope to patients when other treatments fail. However, despite its promise,... Read moreIndustry
view channel
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more